Agenus Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company founded in 1994 and headquartered in Lexington, Massachusetts, discovers, manufactures, and develops therapies that activate the immune system against cancer and infectious diseases. The company focuses on immune checkpoint modulating antibodies including botensilimab, a next-generation CTLA-4 antibody with enhanced Fc functionality, balstilimab, a PD-1 inhibitor, zalifrelimab, a CTLA-4 antibody, and earlier-stage candidates such as AGEN1571 (anti-ILT2), AGEN1777 (TIGIT bispecific), AGEN2373 (CD137), and AGEN1423 (CD73-TGFβ); adoptive cell therapies through its subsidiary MiNK Therapeutics, Inc. (Nasdaq: INKT); and vaccine adjuvants via SaponiQx, Inc., featuring proprietary QS-21 from cultured plant cells and platforms like Retrocyte Display for antibody discovery and AdenoJuice for personalized vaccines. Agenus operates primarily in the United States and Europe, with a pipeline targeting solid tumors such as metastatic colorectal cancer, cervical cancer, and other treatment-resistant malignancies, supported by in-house cGMP manufacturing capabilities. In recent developments, Agenus entered a $141 million strategic collaboration with Zydus Lifesciences in June 2025, exchanging its biologics CMC facilities in Emeryville and Berkeley, California, for $75 million upfront plus up to $50 million in contingent payments, alongside a $16 million equity investment from Zydus and an exclusive manufacturing agreement for botensilimab/balstilimab (BOT/BAL) to support clinical and commercial scale-up. Earlier, in May 2024, the company secured a $100 million royalty financing agreement with Ligand Pharmaceuticals, with potential syndication up to $200 million, to fund BOT/BAL's Phase 3 trial in relapsed/refractory microsatellite stable colorectal cancer and launch activities. Additional advancements include completing enrollment in a Phase 2 BOT/BAL trial in advanced MSS colorectal cancer, receiving Fast Track Designation, launching a Q4 2025 international trial across Canada, France, Australia, and New Zealand, and appointing Dr. José Iglesias as Chief Medical Affairs Officer to expand global access programs.
Company News
Agenus Inc. (NASDAQ:AGEN) Stock Has Consensus Price Target of $24.50 According to Analysts
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
ImageneBio (NASDAQ:IMA) and Agenus (NASDAQ:AGEN) Critical Survey
Agenus (NASDAQ:AGEN) Stock Keeps “Buy” Rating at Chardan Capital
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average – Here’s Why
Agenus to Participate in Upcoming September Investor Conferences
Agenus to Participate in Upcoming September Investor Conferences
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer